Search
Hovione’s Strategy for Complexity, Speed, and Regional Supply Chains
PharmTech, 6 February 2026
How Hovione grew from a basement lab to a global pharmaceutical services company
C&EN, November 12, 2018
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Business Wire, September 23, 2020
Dispersome®
Make your drug soluble with Dispersome® technology. Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Hovione Unveils New Continuous Tableting Line at Lisbon R&D Centre
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Hovione buys Pfizer’s Loughbeg API Facility
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
CheManager, 20 October 2020